Table Info

Table 2.

Percentages of LPR < 1 (across all epitopes of a protein) for all alleles studied, ranked from highest to lowest

Allele	Spike	ORF1ab	Average
A29:02*	0.0493	0.0497	0.0495
A01:01*	0.0441	0.0442	0.0441
A26:01*	0.0415	0.0418	0.0417
A25:01*	0.0428	0.0398	0.0413
A24:02*	0.0402	0.0363	0.0383
A23:01*	0.0415	0.0347	0.0381
B15:01*	0.0350	0.0412	0.0381
A11:01*	0.0337	0.0375	0.0356
A03:01*	0.0286	0.0386	0.0336
A69:01*	0.0299	0.0356	0.0327
B46:01*	0.0312	0.0340	0.0326
B53:01*	0.0324	0.0280	0.0302
A02:02*	0.0247	0.0331	0.0289
B35:01*	0.0286	0.0268	0.0277
B57:01*	0.0221	0.0331	0.0276
B58:01*	0.0208	0.0319	0.0263
A68:01*	0.0221	0.0291	0.0256
C14:02*	0.0234	0.0277	0.0256
B44:03*	0.0234	0.0270	0.0252
B44:02*	0.0234	0.0266	0.0250
A32:01*	0.0208	0.0275	0.0241
A02:05*	0.0234	0.0238	0.0236
B07:02*	0.0247	0.0217	0.0232
A02:01*	0.0195	0.0266	0.0230
A31:01*	0.0260	0.0197	0.0228
B35:03*	0.0234	0.0222	0.0228
A33:01*	0.0221	0.0213	0.0217
B49:01*	0.0221	0.0206	0.0213
B15:03*	0.0195	0.0231	0.0213
A02:06*	0.0208	0.0217	0.0212
B40:01*	0.0169	0.0254	0.0212
B45:01*	0.0234	0.0185	0.0209
B27:05*	0.0234	0.0183	0.0208
B40:02*	0.0182	0.0208	0.0195
B51:01*	0.0195	0.0192	0.0193
B38:01*	0.0182	0.0199	0.0190
C02:02*	0.0182	0.0183	0.0182
C03:02*	0.0195	0.0160	0.0177
B13:02*	0.0182	0.0160	0.0171
C07:02*	0.0195	0.0146	0.0170
C01:02*	0.0182	0.0106	0.0144
B18:01*	0.0130	0.0153	0.0141
C12:02*	0.0169	0.0113	0.0141
C17:01*	0.0143	0.0125	0.0134
C17:03*	0.0143	0.0125	0.0134
B39:01*	0.0091	0.0169	0.0130
C05:01*	0.0078	0.0169	0.0123
C08:02*	0.0091	0.0139	0.0115
C07:01*	0.0130	0.0088	0.0109
C04:01*	0.0104	0.0113	0.0109
C04:43*	0.0104	0.0113	0.0109
C15:02*	0.0104	0.0095	0.0099
C03:04*	0.0078	0.0120	0.0099
B08:01*	0.0091	0.0104	0.0097
B37:01*	0.0091	0.0097	0.0094
C16:01*	0.0104	0.0081	0.0092
C12:03*	0.0104	0.0065	0.0084
C07:04*	0.0091	0.0069	0.0080
C06:02*	0.0078	0.0053	0.0066
C08:01*	0.0052	0.0062	0.0057
B14:02*	0.0026	0.0058	0.0042

Supplementary materials

The supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/10033_sup_1.pdf.

Declarations

Author contributions

SAC and APG contributed to data analysis; SAC, EPT and APG contributed to writing the manuscript.

Conflicts of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Partial funding for this study was provided by the University of Minnesota (the American Legion Brain Sciences Chair) and the U.S. Department of Veterans Affairs. The sponsors had no role in the current study design, analysis or interpretation, or in the writing of this paper. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

Copyright

References

Sanchez-Mazas A, Lemaître JF, Currat M. Distinct evolutionary strategies of human leucocyte antigen loci in pathogen-rich environments. Philos Trans R SocLond B Biol Sci. 2012;367:830–9. [DOI]

Salamon H, Klitz W, Easteal S, Gao X, Erlich HA, Fernandez-Viña M, et al. Evolution of HLA class II molecules: allelic and amino acid site variability across populations. Genetics. 1999;152:393–400. [PubMed] [PMC]

Charonis S, Tsilibary EP, Georgopoulos AP. SARS-CoV-2 virus and Human Leukocyte Antigen (HLA) Class II: investigation of binding affinities for COVID-19 protection and vaccine development. J Immunological Sci. 2020;4:12–23. [DOI]

Charonis S, James LM, Georgopoulos AP. In silico assessment of binding affinities of three dementia-protective Human Leukocyte Antigen (HLA) alleles to nine human herpes virus antigens. Curr Res Transl Med. 2020;68:211–6. [DOI] [PubMed]

The allele frequence database [Internet]. Liverpool: Royal Liverpool University Hospital; c2019 [updated 2019 Jul 10; cited 2020 Jun 16]. Available from: http://www.allelefrequencies.net/

Consortium U. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47:D506–15. [DOI] [PubMed] [PMC]

Immune epitope database and analysis [Internet]. Bethesda: the National Institutes of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID); c2020 [cited 2020 Jun 16]. Available from: http://www.iedb.org

Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48:W449–54. [DOI] [PubMed] [PMC]

Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens. Front Immunol. 2020;11:576622. [DOI] [PubMed] [PMC]

10.

Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27:671–80.e2. [DOI] [PubMed] [PMC]

11.

Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12:254. [DOI]

12.

Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, et al. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. J Virol. 2020;94:e00510–20. [DOI] [PubMed] [PMC]

13.

Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2021;22:74–85. [DOI] [PubMed]

14.

Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65:533–46. [DOI] [PubMed] [PMC]

15.

Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al.; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1,590 patients with COVID-19 in China: a nationwide analysis. EurRespir J. 2020;55:2000547. [DOI]